MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00350233|
Recruitment Status : Completed
First Posted : July 10, 2006
Last Update Posted : September 17, 2012
|Condition or disease||Intervention/treatment||Phase|
|Bone Metastases||Device: ExAblate 2000||Phase 1|
Bone is the third most common organ involved by metastasic disease behind lung and liver. In breast cancer, bone is the second most common site of metastatic spread, and 90% of patients dying of breast cancer have bone metastasis. Breast and prostate cancer metastasize to bone most frequently, which reflects the high incidence of both these tumors, as well as their prolonged clinical courses.
Post cancer survival has increased with improvement in early detection and treatments. As a consequence, the number of patients developing metastatic bone disease during their lifetime has also increased. Patients with bone metastasis from breast cancer have an average 2-year survival from the time of presentation with their first bone lesion. In patients who die from breast, prostate, and lung cancer, autopsy studies have shown that up to 85% have evidence of bone metastases at the time of death.
Current treatments for patients with bone metastases are primarily palliative and include localized therapies (radiation and surgery), systemic therapies (chemotherapy, hormonal therapy, radiopharmaceutical, and bisphosphanates), and analgesics (opioids and non-steroidal anti-inflammatory drugs). Recently, radiofrequency ablation has been tested as a treatment option for bone metastases. The main goals of these treatments are improvement of quality of life and functional level. These goals can be further described: 1) Pain relief, 2) Preservation and restoration of function, 3) Local tumor control, 4) Skeletal stabilization.
The study hypothesis is that MRgFUS is a safe and potentially effective non-invasive treatment for metastatic bone tumors with a low incidence of co-morbidity. Based on the result of this study the Sponsor will initiate a larger study in an effort to approve metastatic bone tumors as an indication for its MRgFUS ExAblate device.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||February 2010|
|Actual Study Completion Date :||February 2010|
|Experimental: ExAblate MRgFUS||Device: ExAblate 2000|
- Determine safety of MRgFUS of Bone Metastases [ Time Frame: Within 1 month of Treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00350233
|United States, California|
|University of California at San Diego|
|LaJolla, California, United States, 92037|
|Toronto General Hospital|
|Toronto, Ontario, Canada, MG5 2C4|
|Principal Investigator:||Christine Chung, M.D.||University of California, San Diego|
|Principal Investigator:||David Gianfelice, M.D.||Toronto General Hospital|